Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

Slični predmeti

• Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial
  od: Christophe Willekens, i dr.
  Izdano: (2016-03-01)
• Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia
  od: Pierre Peterlin, i dr.
  Izdano: (2015-05-01)
• Dexamethasone in hyperleukocytic acute myeloid leukemia
  od: Sarah Bertoli, i dr.
  Izdano: (2018-06-01)
• Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia
  od: Thomas Prebet, i dr.
  Izdano: (2014-10-01)
• Secondary acute myeloid leukemia: time to turn the page
  od: Christian Récher
  Izdano: (2023-07-01)